

Molecular Therapeutics of Cancer Research Conference

Sponsored by the Cancer Molecular Therapeutics Research Association

Skamania Lodge – Stevenson, WA

July 17-21, 2022

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers

****Lodging and meals will be at Skamania Lodge – Stevenson, WA on the Columbia River Gorge****

SUNDAY – JULY 17

- | | |
|------------------|---|
| 4:00 pm | Arrival and check-in (Lobby) |
| 6:00 – 7:00 pm | <i>Dinner</i> |
| 7:30 – 7:45 pm | Welcome / Introductory Comments
Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX,
President CMTRA |
| 7:45 – 9:45 pm | KEYNOTE SPEAKER
Thomas Lynch, Fred Hutchinson Cancer Research Center, Seattle WA,
President and Director |
| 10:00 pm onwards | <i>Opening reception</i> |

MONDAY – JULY 18

- | | |
|-----------------|---|
| 7:30 – 8:15 am | <i>Breakfast</i> |
| 8:30 – 12:00 pm | MORNING SESSION: Interplay between DNA damage responses and antitumor immunity
Discussion Leader: Bob Abraham, Odyssey Therapeutics |
| 8:30 – 8:45 am | Introduction |
| 8:45 – 9:15 am | “How tumors with chromosomal instability evade immune surveillance”
Sam Bakhom, Memorial Sloan Kettering Cancer Center |
| 9:15 – 9:40 am | Discussion |
| 9:40 – 10:00 am | Coffee Break |

10:00 – 10:30 am	“Combining inhibitors of the DNA damage response with immunotherapies to treat cancer” Mark O’Connor, AstraZeneca
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	“Molecular pattern recognition in response to DNA damage” Roger Greenberg, Perelman School of Medicine, University of Pennsylvania
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:45 pm	OPEN NETWORKING AFTERNOON—(Activities Handout)
5:00 – 6:30 pm	Poster Session and Social
6:30 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: Selective Inhibitors of PI3Ka Oncogenic Mutants Discussion Leader: Jim Winkler, OnKure
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	“Discovery and characterization of an allosteric mutant- and isoform-selective inhibitor of PI3K α ” Ermira Pazolli, Relay Therapeutics
8:15 – 8:45 pm	Discussion
8:45 – 9:15 pm	“LOXO-783: A highly potent, brain-penetrant, allosteric inhibitor of PI3K α H1047R that is highly selective against wild-type PI3K α ” Gabrielle R. Kolakowski, Lilly
9:15 – 9:45 pm	Discussion
9:45 pm onwards	<i>Social</i>

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: Targeting Oncogenic KRAS Mutants Discussion Leader: Eli Wallace, BridgeBio
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	“Beyond KRAS G12C: Targeting other KRAS mutant cancers” Jamie Christensen, Mirati
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	<i>Group Picture and Coffee Break</i>
10:00 – 10:30 am	“A KRAS Inhibitor at Last – Elucidating Mechanisms of Resistance and Combination Strategies to Maximize Patient Benefit” Angela Coxon, Amgen
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	“Mechanisms of resistance to KRAS inhibition” Andrew Aguirre, Dana-Farber Cancer Institute
11:30 – 12:00 pm	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
1:00 – 4:45 pm	OPEN NETWORKING AFTERNOON
5:00 – 6:30 pm	Poster Session and Social
6:30 – 7:30 pm	<i>Dinner</i>
7:30 – 9:45 pm	EVENING SESSION: New advances in ADC biology, chemistry and clinical results Discussion Leader: Phil Dennis, Sanofi
7:30 – 7:45 pm	Introduction
7:45 – 8:15 pm	“The Renaissance of Antibody Drug Conjugates—Progress, Challenges & the Future” Puja Sapra, AstraZeneca
8:15 – 8:40 pm	Discussion
8:45 – 9:15 pm	“The Evolving Landscape of Antibody-Drug Conjugates for Targeted Therapy of Cancer” Robert Lyon, Seagen

9:15 – 9:40 pm Discussion

9:40 pm onwards *Social*

WEDNESDAY – JULY 20

7:30 – 8:15 am *Breakfast*

8:30 – 12:00 pm **MORNING SESSION: Advances in the Treatment of Breast Cancer**

Discussion Leader: Lori Friedman, ORIC Pharmaceuticals

8:30 – 8:45 am Introduction

8:45 – 9:15 am “Latest-generation ER-targeted therapeutics in breast cancer: mechanisms & mutations”

Ciara Metcalfe, Genentech

9:15 – 9:40 am Discussion

9:40 – 10:00 am Coffee Break

10:00 – 10:30 am “ER α is an RNA-binding protein sustaining tumor cell survival and drug resistance”
Davide Ruggero, UCSF

10:30 – 10:55 am Discussion

11:00 – 11:30 am “CDK4/6 inhibitors: why they work and how they fail”
Sarat Chandarlapaty, MSKCC

11:30 – 11:55 am Discussion

12:00 – 1:00 pm *Lunch*

2:00 – 3:00 pm **ORAL PRESENTATIONS – Four Selected Presenters from the Poster Abstracts**
TBD

3:00 – 5:30 pm **AFTERNOON SESSION: RAF Beyond BRAF**
Discussion Leader: Shiva Malek, Novartis

3:00 – 3:15 pm Introduction

3:15 – 3:45 pm	“Molecular insights into NRAS mutant driven melanogenesis” Sharon Campbell, UNC
3:45 -4:10 pm	Discussion
4:10 – 4:40 pm	“Chemical Switches and Molecular Glues Regulating KSR-MEK-RAF Complexes” Arvin Dar, Mount Sinai
4:45 – 5:10 pm	Discussion
6:00 – 10:00 pm	<i>Farewell Reception</i>

THURSDAY – JULY 21

7:30 – 8:15 am	<i>Breakfast</i>
11:00 am	Check out by 11:00 am

This meeting would not be possible without the generous contributions from our many sponsors, friends and colleagues

TBA

Our Sponsors

AMGEN[®]

AstraZeneca 

deciphera[™]

Genentech
A Member of the Roche Group

 GILEAD

Janssen 
PHARMACEUTICAL COMPANIES OF
Johnson & Johnson

 Pfizer